Neuroendocrine Tumors of the Pancreas: Molecular Pathogenesis and Perspectives on Targeted Therapies


  • Igor V. Maev Department of Internal Diseases Propaedeutics and Gastroenterology, Moscow State University of Medicine and Dentistry, Delegatskaya Street, 20/1, 127473 Moscow, Russia
  • Dmitry N. Andreev Department of Internal Diseases Propaedeutics and Gastroenterology, Moscow State University of Medicine and Dentistry, Delegatskaya Street, 20/1, 127473 Moscow, Russia
  • Yuriy A. Kucheryavyy Department of Internal Diseases Propaedeutics and Gastroenterology, Moscow State University of Medicine and Dentistry, Delegatskaya Street, 20/1, 127473 Moscow, Russia
  • Diana T. Dicheva Department of Internal Diseases Propaedeutics and Gastroenterology, Moscow State University of Medicine and Dentistry, Delegatskaya Street, 20/1, 127473 Moscow, Russia



Neuroendocrine tumor, multiple endocrine neoplasia type I, von Hippel–Lindau disease, neurofibromatosis type I, tuberous sclerosis, targeted therapy, everolimus, sunitinib.


 Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of neoplasms that are the second most common among pancreatic neoplasms. Treatment of PNETs appears to be quite difficult because diagnosis in many patients occurs only at the latest stage when distant metastases are recognized. Therefore, treatment with drugs targeting PNET oncogenesis is a promising strategy in such patients. In this work, we review the present knowledge on the molecular nature of PNETs, and the genetic basis of PNET-associated hereditary syndromes, including multiple endocrine neoplasia type I, von Hippel-Lindau disease, neurofibromatosis type I, and tuberous sclerosis. In addition, the results of phase III, randomized, placebo-controlled trials of the efficacy of everolimus and sunitinib for treatment of extensive non-resectable PNETs are reviewed.


Miglani A, Kar P. Neuroendocrine tumors of the pancreas. Trop Gastroenterol 2006; 27: 4-10.

Jensen RT, Norton JA. Endocrine tumors of the pancreas and gastrointestinal tract. In: Feldman M, Friedman LS, Brandt LJ, ed. Sleisinger and Fordtrans's gastrointestinal and liver disease, 9th ed. Philadelphia: WB Saunders 2010; 491-522.

Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.

Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G. New treatment strategies in advanced neuroendocrine tumours. Dig Liver Dis 2012; 44: 95-105.

Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology 2012; 83: 117-127.

Verbeke CS. Endocrine tumours of the pancreas. Histopathology 2010; 56: 669-682.

Capurso G, Festa S, Valente R, et al. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol 2012; 49: R37-50.

Rindi G, Bordi C. Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 2005; 19: 519-34.

Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-92.

Oberg K. Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy. Nat Rev Endocrinol 2013; 9: 70-2.

Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-203.

Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumors: Importance and recent advances. Dig Liver Dis 2002; 34: 668-80.

Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72.

Li AF, Li AC, Tsay SH, Li WY, Liang WY, Chen JY. Alterations in the p16INK4a/cyclin D1/RB pathway in gastrointestinal tract endocrine tumors. Am J Clin Pathol 2008; 130: 535-42.

Simon B, Lubomierski N. Implication of the INK4a/ARF locus in gastroenteropancreatic neuroendocrine tumorigenesis. Ann N Y Acad Sci 2004; 1014: 284-99.

Arnold CN, Sosnowski A, Schmitt-Gräff A, Arnold R, Blum HE. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int J Cancer 2007; 120: 2157-64.

Romagosa C, Simonetti S, López-Vicente L, et al. p16 (Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011; 30: 2087-97.

Bartsch D, Hahn SA, Danichevski KD, et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 1999; 18: 2367-2371.

Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-? family signalling. Nature (London) 2003; 425: 577-584.

ten Dijke P, Hill CS. New insights into TGF-?–Smad signalling. Trends Biochem Sci 2004; 29: 265-273.

Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008; 65: 1566-1584.

Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004; 61: 2965-2978.

Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21: 177-184.

Evers BM, Rady PL, Sandoval K, et al. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann Surg 1994; 219(6): 596-601.

Goebel SU, Iwamoto M, Raffeld M, et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 2002; 62: 3702-3710.

Corbo V, Beghelli S, Bersani S, et al. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol 2012; 23: 127-134.

Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003; 9: 1469-1473.

Furukawa M, Raffeld M, Mateo C, et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 2005; 11: 3233-3242.

Peghini PL, Iwamoto M, Raffeld M, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002; 8: 2273-2285.

Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012; 92: 1619-1649.

Koch CA, Gimm O, Vortmeyer AO, et al. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci 2006; 1073: 517-526.

Zhang L, Smyrk TC, Oliveira AM, et al. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol 2009; 33: 1562-1569.

Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113: 1807-1843.

Gaztambide S, Vazquez F, Castaño L. Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva Endocrinol 2013; 38: 17-28.

Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjöld M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.

Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29: 22-32.

Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.

Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57: 4682-4686.

Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004; 1014: 189-198.

Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005; 5: 367-375.

Poisson A, Zablewska B, Gaudray P. Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett 2003; 189: 1-10.

Yang Y, Hua X. In search of tumor suppressing functions of menin. Mol Cell Endocrinol 2007; 265-266: 34-41.

Milne TA, Hughes CM, Lloyd R, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 2005; 102: 749-754.

Karnik SK, Hughes CM, Gu X, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 2005; 102: 14659-14664.

Sato N, Sato M, Nakayama M, Saitoh R, Arai K, Masai H. Cell cycle regulation of chromatin binding and nuclear localization of human Cdc7-ASK kinase complex. Gene Cell 2003; 8: 451-463.

Schnepp RW, Hou Z, Wang H, et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res 2004; 64: 6791-6796.

Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999; 96: 143-152.

Kim H, Lee JE, Cho EJ, Liu JO, Youn HD. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 2003; 63: 6135-6139.

Agarwal SK, Novotny EA, Crabtree JS, et al. Transcriptional factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 2003; 100: 10770-10775.

Heppner C, Bilimoria KY, Agarwal SK, et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001; 20: 4917-4925.

Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003; 113: 881-889.

Hashimoto M, Kyo S, Hua X, et al. Role of menin in the regulation of telomerase activity in normal and cancer cells. Int J Oncol 2008; 33: 333-340.

Jin S, Mao H, Schnepp RW, et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 2003; 63: 4204-4210.

Sukhodolets KE, Hickman AB, Agarwal SK, et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol Cell Biol 2003; 23: 493-509.

Averous J, Proud CG. When translation meets transfor-mation: the mTOR story. Oncogene 2006; 25: 6423-6435.

Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010; 65: 889-893.

Chen M, Van Ness M, Guo Y, Gregg J. Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol 2012; 3: 182-188.

Kasajima A, Pavel M, Darb-Esfahani S, et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011; 18: 181-192.

Di Florio A, Adesso L, Pedrotti S, et al. Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. Endocr Relat Cancer 2011; 18: 541-554.

Wang Y, Ozawa A, Zaman S, et al. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Res 2011; 71: 371-382.

Corcos O, Couvelard A, Giraud S, et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas 2008; 37: 85-93.

Chou A, Toon C, Pickett J, Gill AJ. Von hippel-lindau syndrome. Front Horm Res 2013; 41: 30-49.

Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol 2006; 36: 337-343.

Schmitt AM, Schmid S, Rudolph T, et al. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr Relat Cancer 2009; 16: 1219-1227.

Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 2007; 6: 340-351.

McClatchey AI. Neurofibromatosis. Annu Rev Pathol 2007; 2: 191-216.

Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschläger M. The mTOR pathway and its role in human genetic diseases. Mutat Res 2008; 659: 284-292.

Schwartz RA, Fernández G, Kotulska K, Jó?wiak S. Tuber-ous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007; 57: 189-202.

Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372: 657-668.

Rosner M, Hanneder M, Siegel N, Valli A, Hengstschläger M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res 2008; 658: 234-246.

Briest F, Grabowski P. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics 2014; 4: 336-365.

Stevenson R, Libutti SK, Saif MW. Novel agents in gastroenteropancreatic neuroendocrine tumors. JOP 2013; 14: 152-154.

Oberstein PE, Remotti H, Saif MW, Libutti SK. Pancreatic neuroendocrine tumors: entering a new era. JOP 2012; 13: 169-173.

McCollum AD, Kulke MH, Ryan DP, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004; 27: 485-488.

Yao JC, Shah MH, Ito T, et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.

Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.

Wolin EM. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett 2013; 335: 1-8.




How to Cite

Igor V. Maev, Dmitry N. Andreev, Yuriy A. Kucheryavyy, & Diana T. Dicheva. (2014). Neuroendocrine Tumors of the Pancreas: Molecular Pathogenesis and Perspectives on Targeted Therapies. Journal of Cancer Research Updates, 3(3),  141–150.